ArticleInternational journal of retina and vitreous2025
Short and long-term impact of intravitreal anti-VEGF therapy interruption in retinal vein occlusion during the COVID-19 pandemic: functional outcomes and AI-based fluid analysis of macular edema.
Article in International journal of retina and vitreous, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of the study is to investigate the short- and long-term effects of delayed intravitreal anti-VEGF injections (IVI) for macular edema (ME) in retinal vein occlusion (RVO) patients during the first wave of the COVID-19 pandemic.
methodsThis is a retrospective observational study analyzing a cohort of patients followed at the medical retina department of the Jules Gonin Eye Hospital. During the COVID-19 lockdown, treatment for patients with ME secondary to RVO was deferred due to emergency federal dispositions. The impact on best corrected visual acuity (BCVA) and on OCT changes (i.e. central subfield thickness (CST), intraretinal fluid (IRF), and subretinal fluid (SRF)) were assessed at several time points before and after the lockdown over a 2-year period. The OCT parameters were assessed by the mean of an artificial intelligence (AI) software (Discovery, RetinAI).
resultsA total of 64 patients were included in the study. BCVA significantly decreased following a mean treatment delay of 10 weeks. However, BCVA returned to baseline levels after 6 months, with no significant differences observed after 2-years of follow-up. OCT analysis revealed an increase in CST, IRF and SRF following the treatment delay, which decreased and return to pre-lockdown values after 3 months. No significant differences in OCT parameters were observed at the two-year follow-up.
conclusionThe results of our study suggest that delaying IVI for RVO patients during the COVID-19 lockdown resulted in a temporary decline in BCVA and a recurrence of ME. However, these effects were not sustained long term, as both BCVA and ME control returned to baseline levels by 6 months, with no significant changes observed at the two-year follow-up.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.